TNXP Stock Overview A biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Tonix Pharmaceuticals Holding Corp. Competitors Price History & Performance
Summary of share price highs, lows and changes for Tonix Pharmaceuticals Holding Historical stock prices Current Share Price US$0.34 52 Week High US$14.08 52 Week Low US$0.12 Beta 2.23 1 Month Change 77.97% 3 Month Change 149.15% 1 Year Change -97.38% 3 Year Change -99.99% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Dec 24
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application (Nda) for Tnx-102 Sl for Fibromyalgia Dec 18
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Dec 10
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting Nov 19 Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 Nov 02
Tonix Pharmaceuticals Holding Corp Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) Oct 16 See more updates
Tonix Pharmaceuticals Holding Corp. Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia Dec 24
Tonix Pharmaceuticals Holding Corp. Announces Fda Acceptance of the New Drug Application (Nda) for Tnx-102 Sl for Fibromyalgia Dec 18
Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers Dec 10
Tonix Pharmaceuticals Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting Nov 19 Tonix Pharmaceuticals Holding Corp. Presents Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress-Europe 2024 Nov 02
Tonix Pharmaceuticals Holding Corp Announces Submission of the TNX-102 SL New Drug Application (NDA) for Fibromyalgia to the U.S. Food and Drug Administration (FDA) Oct 16
Tonix Pharmaceuticals Holding Corp. Announces its Single Dose Mpox Vaccine Candidate TNX-801 Aligns with WHO's Newly Issued Preferred Target Product Profile for Mpox Vaccines in Global Health Emergency Sep 16
Tonix Pharmaceuticals Presents Data on the Potential Mpox Vaccine TNX-801 in Using Synthetic Biology to Battle Mpox Vaccine Sep 11
Tonix Pharmaceuticals Holding Corp Announces the Appointment of Thomas Englese as Executive Vice President of Commercial Operations Sep 10 Tonix Pharmaceuticals Holding Corp. (NasdaqCM:TNXP) announces an Equity Buyback for $10 million worth of its shares. Sep 08
Tonix Pharmaceuticals Holding Corp. Presents Data from Two Posters on TNX-102 SL for Reduction of Acute Stress Reaction and Prevention of PTSD and One Poster for Wound Healing at the 2024 Military Health System Research Symposium Aug 29
Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the 2024 Military Health System Research Symposium Aug 28
Tonix Pharmaceuticals Holding Corp. Announces First Patient Enrolled in Phase 2 CATALYST Study of TNX-1300 for the Treatment of Cocaine Intoxication Aug 20 Tonix Pharmaceuticals Holding Corp. Provides Update on the Development of Its Single Dose Live Attenuated Virus Vaccine Candidate for Mpox, Tnx-801, as Who Declares Mpox Outbreak A Global Health Emergency
Tonix Pharmaceuticals Holding Corp. Presents Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia, the Prototypic Nociplastic Pain Syndrome, at the IASP 2024 World Congress on Pain Aug 13 Tonix Pharmaceuticals Holding Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement
Tonix Pharmaceuticals Holding Corp. Announces Potential Positive Impact of U.S. National Academies New Definition of Long COVID on Size of Fibromyalgia Market for Tonmya Aug 01 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $50 million. Jul 31
Tonix Pharmaceuticals Holding Corp. Grants Fast Track Designation by FDA for Tonmya for Fibromyalgia Jul 26
Tonix Pharmaceuticals Holding Corp. Set to File an NDA for Tonmya for the Management of Fibromyalgia, Is Planning Expected Launch in 2H 2025 Jul 18 Tonix Pharmaceuticals Holding Corp. announced that it expects to receive $30 million in funding Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jul 09
Tonix Pharmaceuticals Reports Final Positive Pre-NDA Meeting with FDA for Tonmya™ for the Management of Fibromyalgia Jul 08 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jun 27
Tonix Pharmaceuticals Holding Corp. Presents Vaccine Platform Data in Keynote Talk At the Vaccine Congress 2024 Jun 26
Tonix Pharmaceuticals Holding Corp. Announces Positive Pre-NDA CMC Meeting with FDA for Tonmya for the Management of Fibromyalgia Jun 21 Tonix Pharmaceuticals Holding Corp. has completed a Follow-on Equity Offering in the amount of $4.009881 million. Jun 15
Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Jun 13
Tonix Pharmaceuticals Holding Corp. Announces Two Oral Presentations and One Poster Presentation Involving TNX-1500 Jun 08
ToniTonix Pharmaceuticals Holding Corp. Presents New Data on Tonmya Suggesting Activity for Improvement in Fibromyalgia-Associated Depression Severity in an Oral Presentation at ASCP Annual Meeting Jun 05
Tonix Pharmaceuticals Holding Corp., Annual General Meeting, May 02, 2024 Apr 16 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering in the amount of $4.4 million. Mar 29
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society (Acs) Spring 2024 Meeting Mar 22
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy Mar 08
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans Mar 06
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers Mar 02
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December Feb 17
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024 Feb 15
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD Feb 14
Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of Tnx-102 Sl in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia Jan 10 Tonix Pharmaceuticals Holding Corp. has filed a Follow-on Equity Offering. Dec 22
Tonix Pharmaceuticals Holding Corp. Announces Highly Statistically Significant and Clinically Meaningful Topline Results in Second Positive Phase 3 Clinical Trial of TNX-102 SL for the Management of Fibromyalgia
Tonix Pharmaceuticals Holding Corp. Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity Dec 04
Tonix Pharmaceuticals Holding Corp. Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder Nov 14
National Institute of Allergy and Infectious Diseases Selects Tonix Pharmaceuticals' Vaccine Candidate, TNX-1800, Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials Nov 04
Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Proof-of-Concept Study of TNX-601 ER for the Treatment of Major Depressive Disorder Nov 01
Tonix Pharmaceuticals Holding Corp. Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs Oct 27
Tonix Pharmaceuticals Holding Corp. Receives a Letter from the Listing Qualifications Staff of the Nasdaq Stock Market Oct 21
Tonix Pharmaceuticals Announces Publication of Data in the Journal Nature Involving Tnx-1500 (Fc-Modified Dimeric Anti-Cd40l Mab) for the Prevention of Rejection in Kidney Xenotransplantation in Animal Models Oct 19
Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 UPLIFT Study of TNX-601 ER for the Treatment of Major Depressive Disorder Oct 17
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder Sep 28
Tonix Pharmaceuticals Holding Corp. Announces Poster Presentation Showing Research Results for mTNX-1700 Sep 22
Tonix Pharmaceuticals Holding Corp. Announces Commitment to Supply Tosymra®? (Sumatriptan Nasal Spray) 10 Mg for Treatment of Acute Migraine Sep 07
Tonix Pharmaceuticals Holding Corp. Announces Topline Results from Phase 2 Prevail Proof-Of-Concept Study of TNX-102 SL for the Management of Fibromyalgia-Type Long COVID Sep 06
Tonix Pharmaceuticals Holding Corp. Announces Results of Pre-Ind Meeting with FDA for TNX-801 as A Potential Vaccine to Protect Against Mpox and Smallpox Aug 22
Tonix Pharmaceuticals Initiates Phase 1 Trial of TNX-1500 (Fc-Modified Humanized Anti-Cd40l Mab) in Healthy Volunteers Aug 17
Tonix Pharmaceuticals Completes Enrollment in Potentially NDA-Enabling Phase 3 RESILIENT Trial of TNX-102 SL for Management of Fibromyalgia Aug 02
Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder Aug 01
Tonix Pharmaceuticals Holding Corp. Announces Accelerating Completion of Enrollment in Phase 2 UPLIFT Study of TNX-601 ER (Racemic Tianeptine) for Major Depressive Disorder: Topline Data Now Expected in Fourth Quarter 2023 Jul 27
Tonix Pharmaceuticals Holding Corp. Announces Data Supporting Memory- and Cognition-Enhancing Effects of Racemic Tianeptine and (S)-Tianeptine, But Not (R)-Tianeptine, in Vivo Rat Novel Object Recognition Test Jul 25
Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘Power’ Study of TNX-1900 Intranasal Potentiated Oxytocin for the Treatment of Pediatric Obesity Jul 11 Shareholder Returns TNXP US Biotechs US Market 7D -16.2% 0.7% 0.6% 1Y -97.4% -3.4% 23.7%
See full shareholder returns
Return vs Industry: TNXP underperformed the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: TNXP underperformed the US Market which returned 23.7% over the past year.
Price Volatility Is TNXP's price volatile compared to industry and market? TNXP volatility TNXP Average Weekly Movement 42.7% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.5% 10% least volatile stocks in US Market 3.1%
Stable Share Price: TNXP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: TNXP's weekly volatility has increased from 27% to 42% over the past year.
About the Company Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as rare disease, immunology, and infectious disease product candidates.
Show more Tonix Pharmaceuticals Holding Corp. Fundamentals Summary How do Tonix Pharmaceuticals Holding's earnings and revenue compare to its market cap? TNXP fundamental statistics Market cap US$63.10m Earnings (TTM ) -US$135.25m Revenue (TTM ) US$11.29m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TNXP income statement (TTM ) Revenue US$11.29m Cost of Revenue US$8.95m Gross Profit US$2.34m Other Expenses US$137.59m Earnings -US$135.25m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.72 Gross Margin 20.74% Net Profit Margin -1,197.86% Debt/Equity Ratio 10.8%
How did TNXP perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/30 20:32 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Tonix Pharmaceuticals Holding Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution James Molloy Alliance Global Partners David Buck B. Riley Securities, Inc. Kumaraguru Raja Brookline Capital Markets
Show 7 more analysts 
